pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·28m ago·1 min read
save

Lilly strikes up to $5.9B cancer deal with Stipple Bio

Eli Lilly continues to be pharma’s biggest shopaholic. Lilly has enlisted Cambridge, MA-based startup Stipple Bio for a multibillion-dollar deal to develop new cancer treatments, marking what appears to be the Indianapolis drug giant’s second-largest ...

Nov 16, 2026·read at Endpoints ↗

Stipple Bio CEO Jeff Landau at this year's Endpoints 11 awards (Adam Parshall for Endpoints News) November 16, 2026 04:01 PM EST Deals Lil­ly strikes up to $5.9B can­cer deal with Stip­ple Bio Lei Lei Wu News Reporter Eli Lil­ly con­tin­ues to be phar­ma’s biggest shopa­holic. Lil­ly has en­list­ed Cam­bridge, MA-based start­up Stip­ple Bio for a multi­bil­lion-dol­lar deal to de­vel­op new can­cer treat­ments … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
98 words · retrieved 14m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoAstraZeneca, Alexion's mysathenia gravis treatment enters crowded marketEndpoints
  • 2h agoHelus Pharma notches successful Phase 3 depression readoutEndpoints
  • 5h agoChina's $40k CAR-T; Novartis and Biogen strike dealsEndpoints
  • 5h agoParker Institute's Karen Knudsen: Cancer research has a translation problemEndpoints
  • 6h agoLilly's 14th acquisition of the year is a little-known blood cancer biotechEndpoints